Introduction and commentary: Paving the way for biosimilars in oncology.
作者信息
Abraham Jame
机构信息
Director of Breast Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
出版信息
Semin Oncol. 2013 Dec;40 Suppl 1:S1-4. doi: 10.1053/j.seminoncol.2013.09.014. Epub 2013 Oct 4.
Abstract
摘要
相似文献
1
Introduction and commentary: Paving the way for biosimilars in oncology.
Semin Oncol. 2013 Dec;40 Suppl 1:S1-4. doi: 10.1053/j.seminoncol.2013.09.014. Epub 2013 Oct 4.
2
Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
Semin Oncol. 2014 Feb;41 Suppl 1:S1-2. doi: 10.1053/j.seminoncol.2013.12.003. Epub 2013 Dec 6.
3
Developing oncology biosimilars: an essential approach for the future.
Semin Oncol. 2013 Dec;40 Suppl 1:S5-24. doi: 10.1053/j.seminoncol.2013.09.015.
4
Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s. doi: 10.1200/JOP.2017.026831.
5
[The development of biosimilars in oncology].
Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):721-725. doi: 10.3760/cma.j.issn.0253-3766.2017.10.001.
6
Empower physicians to fight financial toxicity with biosimilars.
Am J Manag Care. 2019 Dec;25(12 Spec No.):SP374-SP375.
7
Biosimilars in oncology: from development to clinical practice.
Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13.
8
From the editor-in-chief: new ways to pay for cures.
Am J Manag Care. 2019 Jun;25(6 Spec No.):SP185.
9
A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
Manag Care. 2019 Jan;28(1):12-15.
10
Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
Semin Oncol. 2014 Apr;41 Suppl 3:S1-2. doi: 10.1053/j.seminoncol.2014.03.010. Epub 2014 Mar 14.
Zotero 插件